ForPatients
by Roche

Nasal Polyps

A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps

Trial Status	Trial Runs In	Trial Identifier
Completed	10 Countries	NCT03280537 2017-001718-28 GA39855

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The purpose of this study is to determine the efficacy and safety of omalizumab compared with placebo in adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who have had an inadequate response to standard-of-care treatments. Study GA39688 (POLYP 1; NCT03280550) was another Phase III study by the Sponsor with identical objectives and design and was run in parallel with this study.

Hoffmann-La Roche	Phase 3
Sponsor	Phase

NCT03280537 2017-001718-28 GA39855
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>= 18 Years & <= 75 Years	No

© 2022 F. Hoffmann-La Roche Ltd